Cargando…

Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin

The Epidermal Growth Factor Receptor (EGFR) is centrally involved in the regulation of key processes of the epithelia, including cell proliferation, survival, differentiation, and also tumorigenesis. Humanized antibodies and small-molecule inhibitors targeting EGFR were developed to disrupt these fu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lulli, Daniela, Carbone, Maria Luigia, Pastore, Saveria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216978/ https://www.ncbi.nlm.nih.gov/pubmed/27322144 http://dx.doi.org/10.18632/oncotarget.10013

Ejemplares similares

The MEK Inhibitors Trametinib and Cobimetinib Induce a Type I Interferon Response in Human Keratinocytes
por: Lulli, Daniela, et al.
Publicado: (2017)

Topical Plant Polyphenols Prevent Type I Interferon Signaling in the Skin and Suppress Contact Hypersensitivity
por: Carbone, Maria Luigia, et al.
Publicado: (2018)

Photo-Oxidation Products of Skin Surface Squalene Mediate Metabolic and Inflammatory Responses to Solar UV in Human Keratinocytes
por: Kostyuk, Vladimir, et al.
Publicado: (2012)

Resveratrol Induces Long-Lasting IL-8 Expression and Peculiar EGFR Activation/Distribution in Human Keratinocytes: Mechanisms and Implications for Skin Administration
por: Pastore, Saveria, et al.
Publicado: (2013)

Intracellular Insulin-like growth factor binding protein 2 (IGFBP2) contributes to the senescence of keratinocytes in psoriasis by stabilizing cytoplasmic p21
por: Mercurio, Laura, et al.
Publicado: (2020)

A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor‐Induced Skin Toxicities
por: Kim, Young Saing, et al.
Publicado: (2019)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Epidermal Growth Factor Receptor Inhibitor Skin Rash Prophylaxis in a Community Oncology Setting
por: Pepper, Micah S., et al.
Publicado: (2018)

Differential Regulation of Type I Interferon and Epidermal Growth Factor Pathways by a Human Respirovirus Virulence Factor
por: Caignard, Grégory, et al.
Publicado: (2009)

Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib‐resistance of EML4‐ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors
por: Taniguchi, Hirokazu, et al.
Publicado: (2016)

Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response
por: Korpela, Sean P., et al.
Publicado: (2021)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
por: Park, Sojung, et al.
Publicado: (2021)

Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Masago, Katsuhiro, et al.
Publicado: (2018)

Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies
por: Li, Yanping, et al.
Publicado: (2022)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Targeting the Cardiotoxicity of Epidermal Growth Factor Receptor Inhibitors
por: Uprety, Dipesh, et al.
Publicado: (2020)

Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells
por: Booy, Stephanie, et al.
Publicado: (2014)

Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors
por: Hofheinz, Ralf-Dieter, et al.
Publicado: (2016)

Role of Systemic Antibiotics in Preventing Epidermal Growth Factor Receptor: Tyrosine Kinase Inhibitors-induced Skin Toxicities
por: Dsouza, Philomena Charlotte, et al.
Publicado: (2017)

Epidermal Growth Factor Receptor Down-Regulation Triggers Human Myoblast Differentiation
por: Leroy, Marina C., et al.
Publicado: (2013)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011)

Redox Imbalance in T Cell-Mediated Skin Diseases
por: Pastore, Saveria, et al.
Publicado: (2010)

Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors
por: Eaby-Sandy, Beth, et al.
Publicado: (2012)

Epidermal growth factor receptor inhibitors related trichomegaly of Eyelashes
por: Maka, Vinayak V., et al.
Publicado: (2014)

The Use of Epidermal Growth Factor Receptor Type 2-Targeting Tyrosine Kinase Inhibitors in the Management of Epidermal Growth Factor Receptor Type 2-Positive Gastric Cancer: A Narrative Review
por: AlMazmomy, Asim M, et al.
Publicado: (2019)

Molecular Determinants of Glioblastoma Response to Epidermal Growth Factor Receptor Kinase Inhibitors
por: Komotar, Ricardo J., et al.
Publicado: (2008)

Regulation of virus-triggered type I interferon signaling by cellular and viral proteins
por: Zhong, Bo, et al.
Publicado: (2010)

Differential induction of interferon stimulated genes between type I and type III interferons is independent of interferon receptor abundance
por: Pervolaraki, Kalliopi, et al.
Publicado: (2018)

Caspase-8 deficiency in epidermal keratinocytes triggers an inflammatory skin disease
por: Kovalenko, Andrew, et al.
Publicado: (2009)

Epidermal Overexpression of Xenobiotic Receptor PXR Impairs the Epidermal Barrier and Triggers Th2 Immune Response
por: Elentner, Andreas, et al.
Publicado: (2017)

Epidermal growth factor receptor inhibitor therapy for recurrent respiratory papillomatosis
por: Moldan, Matthew M., et al.
Publicado: (2013)

Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors
por: Lupu, I, et al.
Publicado: (2015)

Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

Epidermal growth factor receptor inhibitor in advanced basal cell carcinoma
por: Amirabadi, Amir, et al.
Publicado: (2021)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Induces Dry Skin via Decreased in Aquaporin-3 Expression
por: Ikarashi, Nobutomo, et al.
Publicado: (2020)

Type I Interferon Receptor on NK Cells Negatively Regulates Interferon-γ Production
por: Lee, Amanda J., et al.
Publicado: (2019)

Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2
por: Tanaka, Hidekazu, et al.
Publicado: (2014)

A case of epidermal growth factor receptor tyrosine kinase inhibitor effectiveness in epidermal growth factor receptor mutation-positive squamous cell carcinoma
por: Matsumura, Sosuke, et al.
Publicado: (2023)

Type I interferon
por: Niewold, Timothy B.
Publicado: (2020)

Phleboviruses and the Type I Interferon Response
por: Wuerth, Jennifer Deborah, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3eolb3q8c145f9ghaiqt8h9ttt